Omeros Corporation (NASDAQ: OMER) today announced positive data from the company’s Phase 2 clinical trial of OMS721 for the treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE